Physiologically-based Pharmacokinetics (PBPK) Linked to Pharmacodynamics: *In silico* and *in vitro* Parameterization

Michael B. Bolger, Ph.D.

Chief Scientist

Simulations Plus, Inc.

Outline

- PBPK background and principles
  - Pioneers who have influenced our thinking
  - Why PBPK compared to compartmental?
  - Perfusion limited vs. Permeability limited
  - Equations for transport and clearance
- *In silico* generation of organ physiology (PEAR)
- *In silico* calculation of tissue:plasma partition coefficients (and options)
- Examples

Pioneers who influenced our thinking

- **Teorell** (1937)
- **Rowland**: Nestorov, Blakey (*iv* barbiturates), Kawai (*iv, po* cyclosporin), Rodgers (*iv, po* β-blockers)
- **Stanski:** Wada (*iv* thiopental)
- **Krishnan**: Poulin (*in silico* Kps), Haddad (*in silico* organ physiology)
- **Price** (*in silico* organ physiology)
- **Brown** (*in vivo* organ physiology)
- **Sugiyama, Holford, Houston**

Why PBPK?

- Physically relevant model
- Amenable to inter-species scaling
- Simulate Cp vs. time from *in vitro* data
- Explore PK as function of physiology
  - Disease states
  - Variability

Tissue Models

- A fairly complex model:

Vascular Space

Arterial blood

Venous blood

Capillary membrane

Extracellular Space

Cellular membrane

Diffusion/Transport

Intracelluar Space

Metabolism/Clearance

GPEN, Kansas, 2006

Tissue Models

- Blood Compartment:
  - Well Mixed
 - No clearance
  - Linear binding
  - Rapid RBC penetration

$$\frac{dCbo}{dt} = \frac{Q}{V}\left(Cbi - Cbo\right)$$

Cbo, Q, Rbp

Vascular Space
V, Cp, fup

Cbi, Q, Rbp

GPEN, Kansas, 2006

Tissue Models

- **Perfusion Limited Tissue:**
  - Well Mixed
  - Rapid membrane permeation
  - Same unbound concentration in interstitial and intracellular space
  - Preferential partitioning to tissue (Kp)

Cbo, Q, Rbp

Vv, Cv, *fup*

Cbi, Q, Rbp

Vt, Ct, *fut*, CLint

Kp

GPEN, Kansas, 2006

Tissue Models

- **Permeability Limited Tissue**
  - Slow permeation across cell membranes
  - Unbound concentrations in intracellular and interstitial space are different
  - Only unbound drug permeates or is transported

Cbo, Q, Rbp

Vv, Cv, *fup*

Cbi, Q, Rbp

Ve, Ce, Kp

Vt, Ct, *fut*

PStc, Vm, Km

**GPEN, Kansas, 2006**

4

Global Model

GPEN, Kansas, 2006

GastroPlus Generates PBPK Parameters for You

PEAR Physiology™ Generator
    American/Western
    Japanese/Asian
    Rat (single physiology)

Automatically generates all tissue parameters for selected ethnic group, gender, and age.

Generates random samples for Virtual Trials

GPEN, Kansas, 2006

National Health and Nutrition Examination Survey (NHANES) 2001 – 2002 data

- 11,039 people participated
  - 5331 males, 5708 females
  - 3293 Hispanic
  - 4606 Non-Hispanic White
  - 2681 Non-Hispanic Black
  - 459 other race
- Collected Weight, Height, BMI, and bioelectrical impedance (R = Ohms).

GPEN, Kansas, 2006

Kp Calculation Options

PBPK Options

PBPK Settings

Partition Coefficient (Kp) Settings

Kp Prediction Method:

Perfusion Limited Tissues	Permeability Limited Tissues
⦿ Poulin & Theil - Homogeneous	○ Poulin & Theil - Homogeneous
○ Poulin & Theil - Extracellular	⦿ Poulin & Theil - Extracellular
○ User Defined	○ User Defined
○ Rodgers, Leahy, Rowland	○ Rodgers, Leahy, Rowland

Convert Log Pow to Log Poil/water

LogP(Oil) = 1.115 * LogP(ow) + -1.35

Advanced Settings

OK   Cancel

GPEN, Kansas, 2006

(Advanced Settings)

In Silico Tissue Distribution

- Predicting Tissue/Plasma Partition (Kp):
  - Poulin & Thiel

$$Kp = \frac{\left[K \cdot \left(V_{nlt} + 0.3V_{pht}\right)\right] + \left[1 + \left(V_{wt} + 0.7V_{pht}\right)\right]}{\left[K \cdot \left(V_{nlp} + 0.3V_{php}\right)\right] + \left[1 + \left(V_{wp} + 0.7V_{php}\right)\right]} \cdot \frac{fu_p}{fu_t}$$

adipose : $K = D_{vo:w}^*$

other : $K = P_{o:w}$

$\log P_{vo:w} = 1.115 \log P_{o:w} - 1.35$ Leo, Hansch

$fu_t = \left[\left(1 + \left(1 - fu_p\right)/fu_p\right) \cdot RA_{tp}\right]$

V_{nlt}, V_{pht}, V_{wt} : Volume fraction of neutral lipids, phospholipids, water

RA_{tp} : Albumin ratio tissue : plasma

GastroPlus Generates PBPK Parameters for You

Rodgers and Rowland Kps:

$$Kp = Kpu * fup$$

Unbound tissue plasma partition coefficient, *Kpu*, is calculated differently for strong bases than for other drugs.

1. **Strong bases and zwitterions with at least one base pKa ≥ 7** – takes into consideration the unique interaction of bases with acidic phospolipids (details)

$$Kpu = V_{ewt} + \left(\frac{(1/X_{[D],IW})}{(1/X_{[D],P})}V_{iwt}\right) + \left(\frac{Ka[AP]_T((1/X_{[D],IW})-1)}{(1/X_{[D],P})}\right) + \left(\frac{K \cdot V_{nlt} + (0.3K+0.7)V_{pht}}{(1/X_{[D],P})}\right)$$

2. **Acids, Neutrals, and weak bases** – takes into account binding to lipoproteins (neutral drugs) or tissue albumin (acids and weak bases)

$$Kpu = \frac{(1/X_{[D],IW})V_{iwt}}{(1/X_{[D],P})} + V_{ewt} + \left(\frac{K \cdot V_{nlt} + (0.3K+0.7)V_{pht}}{(1/X_{[D],P})}\right) + \left[\left(\frac{1}{fup} - 1 - \frac{K \cdot V_{nlp} + (0.3K+0.7)V_{php}}{(1/X_{[D],P})}\right) \times RA_t\right]$$

$X_{[D]}$ – fraction of neutral drug species in intracellular water (IW, pH=7) and plasma (P, pH=7.4)
K – vegetable oil/water partition coefficient for adipose tissue and 1-octanol/water partition coefficient for remaining tissues
fup-fraction unbound of drug in plasma, Ka – association constant of base with acidic phospholipids, $[AP]_T$ – tissue concentration of acidic phospholipids
RA_t – tissue/plasma lipoprotein or albumin ratio

Factors Impacting Bioavailability

- **Physiological**
  - pH
  - Transit Time
  - Gastric Emptying
  - GI Dimensions
  - Liver Blood Flow
  - Species
  - Sex
  - Food Effects

- **Biochemical**
  - Plasma Protein Binding
  - Liver Enzymes
  - Gastrointestinal
    - Metabolic Enzymes
    - Efflux proteins
    - Transporters
  - Pharmacogenomics

Drug and Excipient Interactions with all of the above.

GPEN, Kansas, 2006


Enterocyte Model for Each Compartment

GPEN, Kansas, 2006

Carrier-mediated Transport

$dM_{ent(i)}/dt =$

        Apical Diffusion Rate

        + Apical Carrier-mediated Transport Rate

        - Basolateral Transfer Rate

        - Gut Metabolism Rate

Apical Carrier-mediated Transport rate =

        $DF_{influx(i)} \, V_{max,influx} \, C_{(i)} / (K_{m,influx} + C_{(i)})$

        $- DF_{efflux\,(i)} \, V_{max,efflux} \, C_{u,ent(i)} / (K_{m,efflux} + C_{u,ent(i)})$

DF = distribution factor for transporter amounts *relative to V_{max} measurement environment* (when Vmax in a compartment is the same as Vmax in the measurement environment, then DF = 1.0).

Transporter Distribution Factors

Lower Vmax   Higher Vmax

First Pass Metabolism

- Gut wall metabolism can be significant, especially for CYP3A4 and CYP2D6 substrates

- Hepatic first pass is a function of the unbound concentration presented to the liver and hepatic blood flow rate

- Changing absorption location and rate can change *both* gut wall metabolism and hepatic first pass metabolism

GPEN, Kansas, 2006

CYP3A4

J

lumen   enterocyte

○ **Drug**
● **Metabolite**

Calculation of hepatic clearance

Houston et al. (1997)

Step 1. *In vitro* incubation of drug with microsomes/hepatocytes/liver slices to obtain enzyme kinetic constants V_{max} and K_m and the *in vitro* intrinsic clearance

CL_{int} *in vitro*

Step 2. Scale *in vitro* enzyme kinetic constants to *in vivo* conditions based on species-specific physiological scale factors.

CL_{int} (whole organ) *in vitro*

Step 3. Based on a hepatic blood flow model (e.g. Venous equilibrium model [1]), determine *in vivo* hepatic clearance. Rate of drug elimination = CL_h × Concentration

CL_h (whole organ) *in vivo*

GPEN, Kansas, 2006

Significance of Gut Metabolism and Controlled Release

Gut Metabolism Scale Factors

Paine MF and Thummel KE, JPET, 1997; 283(3): p. 1552-62.

3A4 (nmol) = 9.7   38.4   22.4

Liver CYP3A = 5489 nmol
Liver Wt. = 1800 g
MicProt = 52.5 mg / g liver
CYP3A4 = 69.7 pmol / mgP

Image J Analysis of
Jejunum vs. Colon Metabolism Scale Factors

Liver CYP3A = 5489 nmol
Jejunum CYP3A4 = 38.4 nmol
Colon CYP3A4 = 0.6 - 6.7 nmol

Jejun........................Colon...........................
6799   226   409 1171 419   855 110

One Jejunum and 10 colon samples. Samples without
Integration numbers were below baseline.

McKinnon, Gut 36(2):259 (1995)

GPEN, Kansas, 2006

Intestinal and Hepatic CYP 3A4 Metabolism: Midazolam, Alprazolam, and Saquinavir

Alprazolam
V_{max} = 2680 pmol/min/mg
K_m = 660 µM
V_{max}/K_m = 4.1
IR Intest. Extract. ~ 1%

Midazolam
V_{max} = 850 pmol/min/mg
K_m = 4 µM
V_{max}/K_m = 212
IR Intest. Extract. = 43%

Saquinavir
V_{max} = 3960 pmol/min/mg
K_m = 0.4 µM
V_{max}/K_m = 9900
IR Intest. Extract. = 64%

Fitzsimmons-DrugMetabDisp-25-2-256-1997-SaquinavirMetabolismIntestine.pdf

GPEN, Kansas, 2006

Intestinal and Hepatic CYP 3A4 Metabolism

Midazolam

MWt = 325.8

Log P = 3.37 (Exp.)

pKa =6.15 Base (ADMET Predictor)

Solubility = 8.7 µg/mL @ pH 7.7 (ADMET Predictor)

Peff = 12 x 10^{-4} cm/s

Dose = 7.5 to 30 mg

CYP 3A4 K_m = 4 µM
V_{max} = 850 pmol/min/mg prot.
V_{maxPed} = 561 pmol/min/mg

Lumped
K_m = 1.21 µg/mL
V_{max} = 0.44 mg/s

OH

H_3C

OH

Cl

F

Paine MF, et al., JPET, 283(3):1552 (1997)

GPEN, Kansas, 2006

Midazolam

Midazolam GFJ effect

Fb=38%
fg=25%

Fb=25%
fg=49%

mg/L

Time

No grapefruit juice

Amounts in Compartments

Liver metabolism   Gut metabolism

Amounts in Compartments

After grapefruit juice (gut Vmax reduced by 62%)

Kupferschmidt HH, Clin. Pharmacol. Therap. 58(1):20 (1995)
Agoram & Bolger, Adv. Drug Deliv. Rev. 50(1):S41 (2001)

GPEN, Kansas, 2006

13

Non-linear Dose Dependence of Midazolam Metabolism in Gut and Liver

	Experimental		GastroPlus Compartmental Simulated				
Dose	Cmax	AUC	Cmax	AUC	Fa%	FDP%	Fb%
7.5	0.028	69	0.021	65	99	45	24
15	0.056	154	0.052	158	99	55	29
30	0.13	453	0.120	369	99	64	34

GastroPlus simulations of non-linear dose dependence for Midazolam.
(Agoram & Bolger, 2001)

Midazolam (New dose design)

- Aim: To design a new formulation of MDZ to minimize first pass
- Method: Avoid gut metabolism by releasing drug in colon
- 0% released at 3h; 100% released at 5h
- F_b increases from 25% to 45%
- E_g reduces from 49% to 6%

Changes in CYP 3A4 Expression in Duodenum of Pediatric Subjects (1 – 12 yo)

a

b

Johnson, T.N., Br. J. Clin. Pharm. 51(5):451 (2001)

GastroPlus with PBPK module:
Pediatric (5 yo) Stochastic population virtual trial:

$V_{max(gut)} = 100\%$, $K_m = 50\%$, SITT = 20%, ColonTT = 20%
Peff = 40%, Other Phys. Params = 10%

Johnson, T.N., Br. J. Anesth. 89(3):428 (2002)

Oxybutynin IR vs CR Integral Tablet

Oxybutynin

IR 2 x 5 mg
Fa = 99%
FDp = 9%
Fb = 6%

Ditropan XL

OROS IT 10 mg
Fa = 33%
FDp = 11%
Fb = 7%

GPEN, Kansas, 2006

Sathyan G, Br. J. Clin. Pharm. 52:409 (2001)

Simulations of Non-Linear Influx Transport

GPEN, Kansas, 2006

Slide 1

Human

Peptide Transporter-1

Peptide Transporter-3

Peptide Histidine
Transporter 1

Human Peptide
Tranporter – 1

β-actin

GPEN, Kansas, 2006

Figure 1. RT-PCR analysis of human PepT1, PTR3, PHT1, and HPT-1 mRNAs in the human esophagus (A), stomach (B), duodenum (C), jejunum (D), ileum (E), ileocecum (F), cecum (G), ascending colon (H), transverse colon (I), descending colon (J), rectum (K), and in Caco-2 cells (L). RT-PCR was performed with specific primers for each mRNA and amplified products of PepT1, PTR3, PHT1, and HPT-1 were 588, 470, 443, and 1004 bp, respectively. Reaction products were electrophoretically separated in 1.4% agarose gels, stained with ethidium bromide (top panels), and identity confirmed by Southern Blot analysis (lower panels). Commercially available human β-actin primers were used to generate a mRNA expression positive control, amplifying a product of 303 bp.

Slide 2

Image J Analysis of Expression

- **PepT1**
  PepT1
  Similar to I

  Valacyclovir
  Gabapentin
  Amoxicillin
 ACE - inhibitors

- **HPT1**
  HPT-1

  Valacyclovir

GPEN, Kansas, 2006

17

Gabapentin

- Substrate for L-type amino acid transporter (LAT1)
  - Similar distribution to PepT1 (high in duodenum)
- Log P = -1.36 (QP)   log $D_{7.0}$ = -2.95 (Exp.)
- Acid pKa = 4.19 and Basic pKa = 10.14 (QP)
- LAT1 IC_{50} = 340 μM (58.2 μg/mL)
- Solubility$_{\sim7.0}$ = 11.9 mg/mL (QP)   30 mg/mL (Exp.)
- $Peff_{QMPR}$ = 0.8 x 10^{-4} cm/s (Passive Transcellular)
- Renal Clearance

GPEN, Kansas, 2006

---

400 mg Solution Dose used to Optimize Compartmental PK

400 mg Solution – 41 yo Female

GPEN, Kansas, 2006

**Predicted and Observed Steady-state
Plasma Gabapentin Concentrations**

(A)

**Predicted Steady-state Plasma Gabapentin
Concentrations Following q6h Administration**

GPEN, Kansas, 2006

# Simulated Non-linear Dose Dependence

Figures 2a,b,c,d show the profiles for all four of the tablet doses.

400 mg PO tablet *tid* Fb = 54%

800 mg PO tablet *tid* Fb= 42%

1200 mg PO tablet *tid* Fb = 37%

1600 mg PO tablets *tid* Fb = 35%

GPEN, Kansas, 2006

19

Non-linear Dose Dependence for Gabapentin Absorption

Gabapentin Fraction of Dose Absorbed

GPEN, Kansas, 2006

# What if we could slowly release Gabapentin with a Gastric Retentive Delivery System once per day?

Gastric Retentive Delivery system

PepT1 and LAT1 highest density.

GPEN, Kansas, 2006

Simulation of Slow Gastric Release


GPEN, Kansas, 2006

---

Monocarboxylate Transporter (MCT-1) Expression in Gut

GPEN, Kansas, 2006

Gill RK, Am. J. Physiol. :Cell Physiol. 289(4):846 (2005)

Gabapentin Prodrug Targeted to MCT1

Gabapentin

XP13512 (Xenoport)

Dose = IR 36 mg-Eq GP / Kg

Dose = IC 10 mg-Eq GP / Kg

Monkey Oral

Monkey Intracolonic

Cundy KC, JPET 311 (1):324 (2004)

Conclusions

- *In silico* estimates of biopharmaceutical properties are useful in early discovery.
- The combination of *in silico*, *in vitro,* and PBPK provide useful simulations prior to *in vivo* testing.
- Significance / Relevance of transporters can be studied with simulation.
- Data Integration is essential.

Acknowledgments

Robert Fraczkiewicz, Ph.D. (ADMET Predictor)

Dechuan Zhang, Ph.D. (ADMET Modeler)

Boyd Steere, Ph.D. (ADMET Modeler)

John Rose, Ph.D. (GastroPlus)

Thome Gilman, Pharm.D. (GastroPlus)

Balaji Agoram, Ph.D. (GastroPlus)

Jason Chittenden, M.S. (GastroPlus)

Viera Lukacova, Ph.D. (GastroPlus PBPK)

John DiBella, M.S. (DDDPlus)

Anand Prabhakaran, M.S. (DDDPlus)

Grace Fraczkiewicz, Ph.D. candidate (Databases)

Walter S. Woltosz, M.S. (CEO)

GPEN, Kansas, 2006

The End

GPEN, Kansas, 2006